Genomic instability in TP53-mutated breast cancer cells treated with etoposide and doxorubicin.

被引：0
|
作者：
De Vos, ML [1 ]
Weber, BL [1 ]
机构：
[1] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
来源：
AMERICAN JOURNAL OF HUMAN GENETICS | 2003年 / 73卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
330
引用
收藏
页码：226 / 226
页数：1
相关论文
共 50 条
  • [31] Exosomal p38 Mitogen-activated Protein Kinase Promotes Tumour Repopulation in TP53-mutated Bile Duct Cancer Cells
    Osawa, Mami
    Matsuda, Yasunobu
    Sakata, Jun
    Wakai, Toshifumi
    ANTICANCER RESEARCH, 2022, 42 (02) : 745 - 757
  • [32] Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells
    Zemanova, Jana
    Hylse, Ondrej
    Collakova, Jana
    Vesely, Pavel
    Oltova, Alexandra
    Borsky, Marek
    Zaprazna, Kristina
    Kasparkova, Marie
    Janovska, Pavlina
    Verner, Jan
    Kohoutek, Jiri
    Dzimkova, Marta
    Bryja, Vitezslav
    Jaskova, Zuzana
    Brychtova, Yvona
    Paruch, Kamil
    Trbusek, Martin
    ONCOTARGET, 2016, 7 (38) : 62091 - 62106
  • [33] Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)
    Savona, Michael R.
    McCloskey, James K.
    Griffiths, Elizabeth A.
    Yee, Karen
    Zeidan, Amer M.
    Al-Kali, Aref
    Deeg, Joachim
    Patel, Prapti
    Sabloff, Mitchell
    Keating, Mary-Margaret
    Dao, Kim-Hien
    Zhu, Nancy
    Gabrail, Nashat Y.
    Fazal, Salman
    Maly, Joseph J.
    Odenike, Olatoyosi
    Kantarjian, Hagop
    DeZern, Amy E.
    O'Connell, Casey L.
    Roboz, Gail J.
    Busque, Lambert
    Buckstein, Rena
    Amin, Harshad
    Randhawa, Jasleen K.
    Leber, Brian
    Oganesian, Aram
    Chan, Winny
    Hao, Yong
    Azab, Mohammad
    Garcia-Manero, Guillermo
    BLOOD, 2022, 140 : 2066 - 2069
  • [34] TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer
    Blee, Alexandra M.
    He, Yundong
    Yang, Yinhui
    Ye, Zhenqing
    Yan, Yuqian
    Pan, Yunqian
    Ma, Tao
    Dugdale, Joseph
    Kuehn, Emily
    Kohli, Manish
    Jimenez, Rafael
    Chen, Yu
    Xu, Wanhai
    Wang, Liguo
    Huang, Haojie
    CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4551 - 4565
  • [35] Ricolinostat enhances adavosertib-induced mitotic catastrophe in TP53-mutated head and neck squamous cell carcinoma cells
    Miyake, Keitaro
    Takano, Naoharu
    Kazama, Hiromi
    Kikuchi, Hiroyuki
    Hiramoto, Masaki
    Tsukahara, Kiyoaki
    Miyazawa, Keisuke
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2022, 60 (05)
  • [36] PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells
    Jaskova, Zuzana
    Pavlova, Sarka
    Malcikova, Jitka
    Brychtova, Yvona
    Trbusek, Martin
    LEUKEMIA RESEARCH, 2020, 89
  • [37] Frequency of the TP53 R337H variant in sporadic breast cancer and its impact on genomic instability
    Carolina Mathias
    Stéfanne Bortoletto
    Ariana Centa
    Heloisa Komechen
    Rubens S. Lima
    Aline S. Fonseca
    Ana Paula Sebastião
    Cícero A. Urban
    Emerson W. S. Soares
    Carolina Prando
    Bonald C. Figueiredo
    Iglenir J. Cavalli
    Luciane R. Cavalli
    Enilze M. F. S. Ribeiro
    Scientific Reports, 10
  • [38] Frequency of the TP53 R337H variant in sporadic breast cancer and its impact on genomic instability
    Mathias, Carolina
    Bortoletto, Stefanne
    Centa, Ariana
    Komechen, Heloisa
    Lima, Rubens S.
    Fonseca, Aline S.
    Sebastiao, Ana Paula
    Urban, Cicero A.
    Soares, Emerson W. S.
    Prando, Carolina
    Figueiredo, Bonald C.
    Cavalli, Iglenir J.
    Cavalli, Luciane R.
    Ribeiro, Enilze M. F. S.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [39] Effect of Vif in doxorubicin treated breast cancer cells
    Bandarra, Susana
    Cipriano, Pedro
    Goncalves, Joao
    Ribeiro, Ana Clara
    Barahona, Isabel
    ANNALS OF MEDICINE, 2021, 53 : S92 - S93
  • [40] Single-Cell Characterization of TP53-Mutated AML Patients Treated with Frontline Azacitidine, Venetoclax, and Magrolimab Reveals Mechanisms of Response and Resistance
    Desai, Poonam N.
    Wang, Bofei
    Reville, Patrick K.
    Jelloul, Fatima Z.
    Borges, Pamella
    Senapati, Jayastu
    Castillo, Micah
    Gunaratne, Preethi
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Daver, Naval
    Abbas, Hussein A.
    BLOOD, 2023, 142
12345